MarketPulse

Radio-DARPin

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Molecular Partners to Showcase Experimental Cancer Therapy MP0712 at Major 2026 Conferences

Molecular Partners will present its DLL3-targeting Radio-DARPin candidate MP0712 at three major scientific conferences in May 2026, highlighting early clinical trial data.
MOLNclinical developmentsmall cell lung cancer
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Molecular Partners Posts $61.7M Loss but Funds Pipeline Through 2028

Molecular Partners reports CHF 61.7M net loss but maintains CHF 93.1M cash runway through 2028, advancing Radio-DARPin and immuno-oncology pipeline programs.
MOLNfinancial resultsclinical trial